KPIs & Operating Metrics(New)
Breakdown Of AssetsCollaboration Revenue BreakdownCollaboration Revenue Breakdown AnnualContractual ObligatonsCost Of SalesDeferred RevenueEmployee StatisticsGross Margin %Gross ProfitIncome (Loss) Before Provision For Income TaxNon Gaap ExpensesNon Gaap Expenses AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of Total Revenue %OPEX SegregationProduct Revenue Breakdown AnnualProfitabilityProperty And Equipment, Net BreakdownRevenue By ProductRevenue By Product %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Total Pmo Product Revenues, Net BreakdownTotal Pmo Product Revenues, Net Breakdown Annual
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Gross Profit (2016 - 2025)

Sarepta Therapeutics has reported Gross Profit over the past 9 years, most recently at $44.2 million for Q4 2025.

  • Quarterly results put Gross Profit at $44.2 million for Q4 2025, down 91.59% from a year ago — trailing twelve months through Dec 2025 was $1.4 billion (down 14.17% YoY), and the annual figure for FY2025 was $1.4 billion, down 14.17%.
  • Gross Profit for Q4 2025 was $44.2 million at Sarepta Therapeutics, down from $248.6 million in the prior quarter.
  • Over the last five years, Gross Profit for SRPT hit a ceiling of $1.0 billion in Q4 2023 and a floor of -$17.5 million in Q3 2022.
  • Median Gross Profit over the past 5 years was $214.0 million (2022), compared with a mean of $286.0 million.
  • Biggest five-year swings in Gross Profit: skyrocketed 20526.66% in 2021 and later crashed 110.75% in 2022.
  • Sarepta Therapeutics' Gross Profit stood at $169.7 million in 2021, then soared by 339.68% to $746.2 million in 2022, then soared by 38.56% to $1.0 billion in 2023, then crashed by 49.12% to $526.1 million in 2024, then tumbled by 91.59% to $44.2 million in 2025.
  • The last three reported values for Gross Profit were $44.2 million (Q4 2025), $248.6 million (Q3 2025), and $458.5 million (Q2 2025) per Business Quant data.